Travere Therapeutics Inc. (NASDAQ:TVTX) closed Wednesday at $20.59 per share, up from $20.38 a day earlier. While Travere Therapeutics Inc. has overperformed by 1.03%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TVTX fell by -26.57%, with highs and lows ranging from $30.35 to $17.97, whereas the simple moving average fell by -14.16% in the last 200 days.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
On December 14, 2022, Stifel started tracking Travere Therapeutics Inc. (NASDAQ: TVTX) recommending Hold. A report published by Wells Fargo on December 05, 2022, Initiated its previous ‘Overweight’ rating for TVTX. Bryan Garnier also rated TVTX shares as ‘Sell’, setting a target price of $17 on the company’s shares in an initiating report dated September 21, 2022. Canaccord Genuity Initiated an Buy rating on July 14, 2022, and assigned a price target of $42. Piper Sandler initiated its ‘Overweight’ rating for TVTX, as published in its report on March 31, 2022. H.C. Wainwright’s report from February 28, 2022 suggests a price prediction of $45 for TVTX shares, giving the stock a ‘Buy’ rating. Wedbush also rated the stock as ‘Neutral’.
Analysis of Travere Therapeutics Inc. (TVTX)
Further, the quarter-over-quarter decrease in sales is -21.60%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Travere Therapeutics Inc.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -137.70% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.00, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and TVTX is recording an average volume of 829.66K. On a monthly basis, the volatility of the stock is set at 4.94%, whereas on a weekly basis, it is put at 4.96%, with a loss of -1.86% over the past seven days. Furthermore, long-term investors anticipate a median target price of $31.83, showing growth from the present price of $20.59, which can serve as yet another indication of whether TVTX is worth investing in or should be passed over.
How Do You Analyze Travere Therapeutics Inc. Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.20%. This can enable you to see the extent to which executives own the company’s stock.
Are institutional investors increasing their holdings in TVTX shares?
The recent increase in stakes in TVTX appears to be a result of several institutional investors and hedge funds increasing their positions. Armistice Capital LLC’s position in TVTX has increased by 9.70% in the first quarter. The company now owns 5,836,000 shares of the stock, with a value of $117.48 million, following the purchase of 516,000 additional shares during the last quarter. During the last quarter, the company picked up 0 additional shares for a total stake of worth $99.1 million, bringing number of shares owned by the company to 4,922,941.
During the first quarter, Deep Track Capital LP added a 419,300 position in TVTX. BlackRock Fund Advisors sold an additional 20625.0 shares in the last quarter, decreasing its holdings by -0.52%, now holding 3.93 million shares worth $79.11 million. At the end of the first quarter, Adage Capital Management LP increased its TVTX holdings by 67.11% and now holds 3.93 million TVTX shares valued at $79.05 million with the added 1.58 million shares during the period.
